Dr. Elisabeth Heath, colleagues, receive renewed federal funding for prostate cancer research
Tuesday, April 29, 2014
Elisabeth Heath, M.D., F.A.C.P., director of Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute and professor of Oncology and Medicine at Wayne State University School of Medicine, along with her prostate cancer research colleagues, has received renewed grant funding by the U.S. Department of Defense (DOD) for the Institute’s participation in the Prostate Cancer Clinical Trials Consortium.
Dr. Heath, who is also the Hartmann Endowed Chair for Prostate Cancer Research, and her team have been part of the consortium since 2008. The renewal allows them to be part of the consortium and to receive funding for another three years.
The grant will award $912,000 towards the clinical trials infrastructure necessary to conduct translational prostate cancer research studies. To date, the Department of Defense has provided $1,519,071 to the Karmanos investigators.
Karmanos was one of only 11 institutions nationwide selected in a rigorous, peer-reviewed process through the Department of Defense to take part in the consortium.
“Receiving funding is a highly-competitive process and the consortium is a highly-coveted group to be in since prostate cancer experts from major centers are involved,” Dr. Heath said. “Being part of the consortium allows us to conduct and participate in cutting-edge clinical trials, which will ultimately benefit our prostate cancer patients.”
The Prostate Cancer Clinical Trials Consortium was initially formed in 2005 by the Prostate Cancer Foundation and the DOD’s Prostate Cancer Research program. It was established in response to gaps identified in prostate cancer clinical research by physician investigators and prostate cancer advocates.
The consortium is now a major, multi-institutional clinical research organization that includes a nationwide network of physicians at 13 academic institutions specializing in cutting-edge prostate cancer research, with a single coordinating center located at Memorial Sloan-Kettering Cancer Center in New York.
Consortium members work together on a single mission – to design, implement and complete hypothesis-driven Phase I, II and III trials in prostate cancer, translating scientific discoveries into improved standards of patient care.
We congratulate Dr. Heath and her team for receiving grant funding and for inclusion in the Prostate Cancer Clinical Trials Consortium.